Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1
In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated…
Read the full articleYou might also wanna read
Addressing Domestic Violence Risks in Multiple Sclerosis Care
This Viewpoint examines the high prevalence, risk factors, health impacts, and underrecognition of domestic violence among people with multi
doi.org·1mo ago
ClinicalTrials.gov
New clinical trial Disability Progression in Multiple Sclerosis: Determinants, Pathophysiology, and Global Health Impact #ClinicalTrials #Mu
clinicaltrials.gov·1mo agoVumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry
Brief summary This is a global, prospective, observational pregnancy exposure registry designed to evaluate pregnancy and infant outcomes fo
RE: Valproate use in women aged 15–44 years: an observational study in general practice
Agreement I do not Agree Body Dear authors, I was very interested to read your article regarding the prescription of valproate in women of c
Q&A 174: multiple sclerosis and psoriasis
I have seen a handful of patients who prioritise their treatment of psoriasis with one of the licensed biological therapies for psoriasis.
Comments
Sign in to join the conversation.
No comments yet. Be the first.